Nuzenio

Protara Therapeutics

Protara Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 3 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - pluang.compluang.com · Tue, 11 Aug 2026 07:03:23 GMTProtara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key Levels - Dark Pool Sentiment - dars.gov.etdars.gov.et · Sat, 08 Aug 2026 00:37:03 GMTProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeatMarketBeat · Tue, 04 Aug 2026 06:18:59 GMT

Timeline

Tue, 11 Aug 2026 07:03:23 GMTProtara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - pluang.com
Sat, 08 Aug 2026 00:37:03 GMTProtara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key Levels - Dark Pool Sentiment - dars.gov.et
Tue, 04 Aug 2026 06:18:59 GMTProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Protara Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.